ERBB2 and breast carcinoma: Conventionally, breast cancer is not a highly immunogenic cancer when compared with tumors such as melanoma and NSCLC, but detection of tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancer (TNBC) and HER2+ breast tumors, and the association of these lymphocytes with pathological complete response (pCR) to treatment, highlighted the importance of the immune system in breast cancer [80].